These revised SCDAT Guidelines were originally published by the Work Group on Drugs of Abuse Testing (AGSA). The SCDAT, successor to AGSA, is a work group composed of members of the following institutions:
• Swiss Association of Pharmacists (pharmaSuisse)
• Swiss Society of Clinical Chemistry (SGKC)
• Swiss Society of Legal Medicine (SGRM)
• Swiss Association of the Diagnostic Equipment and Product Industry (SVDI)
• University of Bern.
These guidelines are intended as recommendations. They are not legally binding in nature. Harmonization in drug analyses is the objective. The use of drug analysis for the various questions in the therapeutic and forensic sectors as well as in specific workplaces can have far-
The guidelines are periodically revised and enlarged.
In addition, the SCDAT provides consultation both to the laboratories that conduct drug testing and the Swiss Quality Control Centers (inter-
Although SCDAT takes the utmost care in assuring the correctness of the information in printed or electronic form, it does not assume liability with regard to the correctness, accuracy, timeliness, reliability, and comprehensiveness of this information as contained herein. SCDAT expressly reserves the right to alter, delete, or temporarily refrain from publishing the contents, in full or in part, at any time without prior notice thereof. Any liability claims against SCDAT for damages of a material or immaterial nature ensuing from the access to, the use or non-